GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » Equity-to-Asset
中文

Sientra (Sientra) Equity-to-Asset : -0.23 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Sientra Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sientra's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-32.05 Mil. Sientra's Total Assets for the quarter that ended in Sep. 2023 was $139.93 Mil. Therefore, Sientra's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was -0.23.

The historical rank and industry rank for Sientra's Equity-to-Asset or its related term are showing as below:

SIENQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.38   Med: 0.3   Max: 0.85
Current: -0.23

During the past 11 years, the highest Equity to Asset Ratio of Sientra was 0.85. The lowest was -2.38. And the median was 0.30.

SIENQ's Equity-to-Asset is ranked worse than
94.02% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs SIENQ: -0.23

Sientra Equity-to-Asset Historical Data

The historical data trend for Sientra's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra Equity-to-Asset Chart

Sientra Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.40 - 0.20 -

Sientra Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 - -0.07 -0.13 -0.23

Competitive Comparison of Sientra's Equity-to-Asset

For the Medical Devices subindustry, Sientra's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sientra's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sientra's Equity-to-Asset falls into.



Sientra Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sientra's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-0.409/165.421
=-0.00

Sientra's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-32.045/139.933
=-0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sientra  (OTCPK:SIENQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sientra Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sientra's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (Sientra) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.
Executives
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes director, officer: President and CEO 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F. director 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett officer: General Counsel and VP 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg director 420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole director C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller officer: VP, Controller and Interim CFO
Paul Sean Little officer: Chief Financial Officer SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent director 1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines director, 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison director C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054

Sientra (Sientra) Headlines

From GuruFocus

Q2 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024